GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » Net Debt Paydown Yield %

Aerovate Therapeutics (Aerovate Therapeutics) Net Debt Paydown Yield % : 0.05% (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Aerovate Therapeutics's Net Debt Paydown Yield % was 0.05%.


Aerovate Therapeutics Net Debt Paydown Yield % Historical Data

The historical data trend for Aerovate Therapeutics's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerovate Therapeutics Net Debt Paydown Yield % Chart

Aerovate Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
- - - -0.06 0.03

Aerovate Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.06 -0.02 0.03 0.04

Competitive Comparison of Aerovate Therapeutics's Net Debt Paydown Yield %

For the Biotechnology subindustry, Aerovate Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerovate Therapeutics's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's Net Debt Paydown Yield % falls into.



Aerovate Therapeutics Net Debt Paydown Yield % Calculation

Aerovate Therapeutics's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 1.11-0.78 )/824.967516
=0.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Aerovate Therapeutics  (NAS:AVTE) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Aerovate Therapeutics Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerovate Therapeutics (Aerovate Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
930 Winter Street, Suite M-500, Waltham, MA, USA, 02451
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Executives
Hunter Gillies officer: Chief Medical Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Ralph Niven officer: Chief Development Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Benjamin T Dake officer: See Remarks C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Marinus Verwijs officer: SENIOR VICE PRESIDENT, CMC C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes director, officer: Chief Executive Officer 1365 MAIN STREET, WALTHAM MA 02451
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot officer: Chief Commercial Officer AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George A Eldridge officer: See Remarks C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Maha Katabi director, 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116